Clinical Trials
15 trialsNCT06540872 2026-06-03
MI-CISDIR
Universität Münster
Phase 2 Recruiting
NCT06075953 2026-05-22
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT06195306 2026-05-20
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05941520 2026-05-13
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06184750 2026-05-13
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04169542 2026-05-04
Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery
M.D. Anderson Cancer Center
Recruiting
NCT06538389 2026-04-30
High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer
City of Hope Medical Center
Phase 2 Recruiting
NCT06868238 2026-04-30
Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS)
University of Florida
Phase 2 Recruiting
NCT03448926 2026-04-17
PREDICT
PreludeDx
Recruiting
NCT02918474 2026-04-16
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
M.D. Anderson Cancer Center
Phase NA Recruiting
NCT06902311 2026-03-30
H-ASSIST
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT07478016 2026-03-17
EXIST
Thomas Jefferson University
Recruiting
NCT03909282 2026-03-12
NORDIS
Stanford University
Phase NA Recruiting
NCT06218303 2026-03-12
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
University of Pittsburgh
Phase 1 Recruiting
NCT04144023 2026-03-05
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
Mayo Clinic
Phase 1 Recruiting